KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Melatonin supplementation for quality of life in older patients with advanced cancer: a randomized controlled trial. PMID 41421991 · BMC Geriatr · 2025-Dec-20 The trial is a randomized controlled trial in oncology patients, but it does not meet key eligibility criteria. The phase is not specified as Phase III/IIIb or Phase II/III. The intervention is melatonin (a dietary supplement), not a drug. The primary endpoint is quality of life, and while survival is mentioned as a secondary objective, the results do not present a primary/key secondary time-to-event efficacy endpoint (OS, PFS, etc.) with Kaplan-Meier or HR analysis.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
177Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study. PMID 41223345 · J Clin Oncol · 2025-Dec-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The impact of early nutritional care intervention on gastrointestinal function, immune function and nutritional indicators in patients after radical surgery for esophageal cancer: A single-center, observational study. PMID 41431032 · Medicine (Baltimore) · 2025-Dec-19 Excluded due to lack of drug intervention and lack of time-to-event efficacy endpoint. The study is a randomized trial of nutritional care, not a drug.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
O04 Mission EB -mesenchymal intravenous stromal cell infusions in children with recessive dystrophic epidermolysis bullosa: a randomised, double-blinded, placebo controlled, crossover trial. PMID 41412990 · Br J Dermatol · 2025-Dec-19 The record describes a Phase II crossover trial of a cell therapy (mesenchymal stromal cells) in pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB), a genetic disorder with cancer risk but not a primary malignancy trial. The main efficacy endpoints are disease severity scores, wound appearance, pain, itch, and quality of life, not time-to-event outcomes (OS, PFS, DFS, etc.). The abstract explicitly states 'Results will be discussed at the meeting', indicating this is a protocol or interim presentation without final results. The intervention is a cell product, not a conventional drug, and the phase is not Phase III/IIIb or definitive Phase II/III. Therefore, it does not meet the criteria for inclusion in the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Reconstruction after distal gastrectomy and alkaline gastritis: a multi-center three-arm randomized trial comparing Billroth-II, Billroth-II Braun, and Uncut Roux-en-Y (SDR-02). PMID 41417990 · Int J Surg · 2025-Dec-18 This is a randomized Phase III trial in human gastric cancer, but the intervention is purely surgical (reconstruction methods) with no drug component. The primary endpoint is the incidence of bile reflux at 3 months (a categorical outcome), not a time-to-event efficacy endpoint. Therefore, it does not meet the drug intervention or time-to-event criteria.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy, safety and immunogenicity of a recombinant human papillomavirus bivalent (types 16, 18) vaccine in healthy 18-30-year-old Chinese women: a phase III, double-blind, randomized, controlled trial. PMID 41413453 · BMC Infect Dis · 2025-Dec-18 The study is a randomized, placebo-controlled Phase III trial of a drug (HPV vaccine) with an oncology indication (prevention of cervical neoplasia). However, the primary efficacy endpoint is the proportion developing CIN2+, a categorical outcome, not a time-to-event endpoint like OS, PFS, or DFS. No Kaplan-Meier curves, hazard ratios, or other time-to-event analyses are reported in the abstract. Therefore, it does not meet the required time-to-event efficacy endpoint criterion.
H L B
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
LEF1 intragenic deletion induces a dominant-negative isoform and unveils a Wnt/β-catenin vulnerability in T-ALL. PMID 40857670 · Blood · 2025-Dec-18 The abstract describes a biomarker/genetic analysis (LEF1 alterations) from Phase II/III T-ALL trial cohorts but does not report a primary or key secondary time-to-event efficacy endpoint (like OS, PFS, etc.) with Kaplan-Meier or HR results. It focuses on biological insights and treatment response associations, not definitive trial outcome data.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Interrater reliability in the assessment of oral mucositis among patients receiving high-dose chemotherapy: a multicenter comparison between specialized dentists and registered nurses. PMID 41408611 · BMC Cancer · 2025-Dec-17 The report is a methodological sub-study (interrater reliability) from a Phase III oncology trial, not the primary efficacy analysis. It lacks a time-to-event efficacy endpoint and does not report original trial results for a drug intervention.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Can we Save the rectum by watchful waiting or transanal microsurgery following shorT-course radiotherapy and Additional local oR systemic Treatment for early-stage REctal Cancer? STARTREC-3 protocol for a non-randomised, multicentre, phase II platform study. PMID 41407426 · BMJ Open · 2025-Dec-17 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Ambulatory laparoscopic colorectal surgery management paradigm with initial experience: a prospective randomized clinical trial. PMID 41405332 · Int J Surg · 2025-Dec-17 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Comparative Effectiveness of Text + Video vs Text Alone to Prompt Stool-Based Testing for Colorectal Cancer Screening. PMID 41042066 · Perm J · 2025-Dec-15 The study is an oncology-related randomized trial with a time-to-event endpoint, but it lacks a drug intervention and does not meet the phase criterion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial. PMID 40772855 · Clin Cancer Res · 2025-Dec-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Long-term Efficacy and Safety of Amifampridine Phosphate (Firdapse®) in Japanese Patients with Lambert-Eaton Myasthenic Syndrome (LMS-005 Study). PMID 40533232 · Intern Med · 2025-Dec-15 未发现恶性肿瘤人群证据。
B
仅广召回影子组 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Photodynamic therapy: An alternative technique to cervical conization for cervical dysplasia. PMID 41389709 · Med · 2025-Dec-12 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Impact of enteral Ecoimmunonutrition on immunological response, nutritional status and tolerance to treatment in gastrointestinal malignancy patients receiving chemotherapy. PMID 41387645 · Support Care Cancer · 2025-Dec-12 The study is a randomized controlled trial in oncology with a drug-containing intervention, but it lacks any explicit time-to-event efficacy endpoint (like OS, PFS, DFS, etc.) or associated statistical results (Kaplan-Meier, HR). The reported outcomes are immunological, nutritional, quality of life, and preclinical tumor growth. Phase is not specified as III/IIIb or definitive.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy of ozoralizumab in rheumatoid arthritis patients with large joint involvement: a post hoc analysis of OHZORA and NATSUZORA trials. PMID 41381211 · RMD Open · 2025-Dec-11 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Transcatheter arterial chemoembolization with or without bevacizumab in hepatocellular carcinoma with portal vein invasion: a randomized trial. PMID 41373028 · Cancer Imaging · 2025-Dec-10 Study is a randomized trial with drug intervention and time-to-event endpoints, but the phase is not explicitly established as Phase III/IIIb or Phase II/III in the provided metadata, which is required for eligibility.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
An efficient single-arm Bayesian adaptive trial algorithm to evaluate de-intensified oncologic treatment. PMID 41372997 · Trials · 2025-Dec-10 The record describes a methodological paper for a Bayesian adaptive trial design, not a report of results from a randomized drug intervention trial. It is a single-arm design simulation/validation study, not a Phase II/III randomized trial with a drug-containing intervention and a primary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
First-line medical thoracoscopy for pleural infection: the SPIRIT randomised controlled feasibility trial. PMID 41371905 · BMJ Open Respir Res · 2025-Dec-10 The study is excluded because it is not oncology-related, lacks a drug intervention, is a feasibility study (not Phase III), and does not report time-to-event efficacy endpoints.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparing the efficacy and safety of the ABC-14 regimen (azacitidine, venetoclax, and chidamide) with traditional "3 + 7" intensive induction regimen or AB-14 regimen (venetoclax combined with azacitidine) in newly diagnosed AML: study protocol for a prospective, multicenter, randomized, open-label clinical trial. PMID 41366419 · Trials · 2025-Dec-10 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Clinical Significance of Intratumoral Contrast Pooling on Contrast-Enhanced CT After Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma. PMID 41440222 · Curr Oncol · 2025-Dec-09 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
EORTC 1417 - REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer. PMID 41192233 · Eur J Cancer · 2025-Dec-09 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Body and Mind Programme for recovery from breast cancer: Evaluation of the impact of health promotion intervention carried out in a multidisciplinary team on health-promoting behaviours: a quasi-randomised-controlled clinical trial. PMID 41353158 · BMC Psychol · 2025-Dec-07 The study is a quasi-randomized controlled trial evaluating a non-drug health promotion intervention for breast cancer patients. It lacks a drug intervention and a primary time-to-event efficacy endpoint, and the phase is not established as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparison of laparoscopic and open stand-alone feeding jejunostomy in patients with proximal gastrointestinal tract malignancies: An open-label randomised controlled trial. PMID 41351262 · J Minim Access Surg · 2025-Dec-05 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Serum protein profiles differ with adalimumab and ustekinumab treatment in moderately to severely active Crohn's disease. PMID 41258994 · J Crohns Colitis · 2025-Dec-05 The record is from a Phase III randomized trial with a drug intervention and original results, but it is excluded because the condition (Crohn's disease) is not oncology, and the study does not have a primary/key time-to-event efficacy endpoint as required.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Endoscopic or surgical gastroenterostomy for malignant gastric outlet obstruction: a randomised trial. PMID 40998416 · Gut · 2025-Dec-05 The trial is a randomized, multicenter study in patients with malignant gastric outlet obstruction, which is oncology-related. It reports primary results of a randomized comparison. However, it is excluded because the intervention (endoscopic vs. surgical gastroenterostomy) is not a drug-containing intervention, and the primary endpoint is a composite clinical outcome measure, not a time-to-event efficacy endpoint like overall survival or progression-free survival. No Kaplan-Meier curves or hazard ratios are mentioned.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The Surveillance After Extremity Tumor Surgery (SAFETY) Pilot International Multi-Center Randomized Controlled Trial. PMID 41440214 · Curr Oncol · 2025-Dec-04 This is an oncology, human, randomized pilot trial evaluating a non-drug intervention (surveillance frequency and imaging modality) for soft-tissue sarcoma. It lacks a drug-containing intervention and a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR). The report describes feasibility and aggregate outcomes, not a definitive Phase III/IIIb trial with a drug.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
PERi-operative Selective Decontamination of the digestive tract to prevent severe infectious complications after Esophageal Resection: study protocol of the PERSuaDER-trial, a multicenter randomized controlled trial in patients with primary resectable esophageal carcinoma. PMID 41345690 · Trials · 2025-Dec-04 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Comparison of short-term outcomes and oncological outcomes between totally laparoscopic distal gastrectomy and pylorus-preserving gastrectomy for early gastric cancer in the middle stomach: a non-inferiority randomised controlled trial. PMID 41482811 · Int J Surg · 2025-Dec-03 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial. PMID 41339350 · Nat Commun · 2025-Dec-03 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Laparoscopic versus open distal gastrectomy with D2 lymphadenectomy following neoadjuvant chemotherapy for locally advanced gastric cancer (CLASS-03b): protocol for a multicentre, randomised, controlled, non-inferiority trial. PMID 41338637 · BMJ Open · 2025-Dec-03 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Transtympanic sodium thiosulphate to prevent cisplatin-related hearing loss: a protocol for randomised controlled multicentre phase III trial, the SOUND trial. PMID 41338634 · BMJ Open · 2025-Dec-03 方案论文未报告临床试验结果。
H B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Effect of the index of consciousness 2 on intraoperative opioid dosage in ovarian cancer patients receiving neoadjuvant chemotherapy: a study protocol for a randomised controlled trial. PMID 41338618 · BMJ Open · 2025-Dec-03 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Comparison of the EndoGIA versus the Endowrist stapler in intracorporeal urinary diversion in robotic assisted radical cystectomy (EGIAES) - a randomized multicentre trial. PMID 41335393 · J Robot Surg · 2025-Dec-03 The study is a randomized controlled trial in oncology (bladder cancer) with a primary efficacy endpoint, but the intervention is a comparison of surgical stapler devices (non-drug-only), and the primary endpoint (time to first flatus/bowel movement, POI rate, LOS) is not a time-to-event efficacy endpoint as defined (OS, PFS, DFS, etc.).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of Anthelmintic Therapy for Invasive Helminth Infection on Microbial Translocation, Inflammation, and Immune Response among Ugandans Living with HIV: A Randomized Proof of Concept Study. PMID 41130223 · Am J Trop Med Hyg · 2025-Dec-03 The study is a randomized proof-of-concept trial evaluating anthelmintic therapy for helminth infection in people living with HIV. It is not a study of a human malignant neoplasm (cancer). Therefore, it does not meet the primary inclusion criterion of being an oncology study.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of Health Education on Cervical Cancer Screening Uptake and Knowledge among Target Women in Addis Ababa: A Randomized Controlled Trial. PMID 40878788 · Cancer Prev Res (Phila) · 2025-Dec-02 The study is a randomized controlled trial in oncology (cervical cancer prevention), but it is excluded because it lacks a drug-containing intervention (it uses health education), does not report a time-to-event efficacy endpoint (primary outcome is screening uptake proportion), and is not a definitive Phase III/IIIb trial (phase not specified).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Endocrine therapies and mortality risk in postmenopausal women with breast cancer: benchmarking an observational analysis against a randomized trial. PMID 40838592 · Am J Epidemiol · 2025-Dec-02 The record describes a methodological paper benchmarking an observational study against the BIG 1-98 randomized trial. While the referenced trial (BIG 1-98) was a Phase III RCT with drug intervention (letrozole vs. tamoxifen) and a time-to-event endpoint (risk of death), the provided abstract is not the original formal-result report of that trial. It is an observational analysis and benchmarking study. Therefore, it is not an eligible original result report of a clinical trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Postoperative SBRT and Severe Late Toxic Effects in Early-Stage Oropharyngeal and Oral Cavity Cancers: The STEREOPOSTOP-GORTEC 2017-03 Nonrandomized Clinical Trial. PMID 41632122 · JAMA Netw Open · 2025-Dec-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The Effectiveness of Acceptance and Commitment Therapy on Fear of Cancer Recurrence in Patients with Gastrointestinal Cancer with a Stoma: A Randomized Controlled Trial. PMID 41459871 · Asian Pac J Cancer Prev · 2025-Dec-01 The study is an oncology RCT with a psychological intervention, not a drug intervention, and does not report a time-to-event efficacy endpoint like OS/PFS.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Five-Day Preoperative Radiation Therapy for Patients With High-Risk Soft Tissue Sarcoma: A Nonrandomized Clinical Trial. PMID 41405883 · JAMA Netw Open · 2025-Dec-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Long-term outcomes of ripretinib versus sunitinib in Chinese patients with advanced gastrointestinal stromal tumor: An updated analysis of a phase 2 randomized clinical trial. PMID 41363834 · Cancer · 2025-Dec-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Preoperative Weight Loss in Patients With Excess Weight and Colorectal Cancer: The CARE Feasibility Randomized Clinical Trial. PMID 41359334 · JAMA Netw Open · 2025-Dec-01 The trial is oncology-focused, human, randomized, and reports original results. However, it is a feasibility/pilot study, not a definitive Phase III trial, and its intervention is a dietary program, not a drug. Furthermore, the study does not report any time-to-event efficacy endpoint (e.g., OS, PFS, DFS) with Kaplan-Meier analysis or hazard ratio.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Evaluating Food and Drug Administration approved gastrointestinal cancer drugs: clinical benefit and trial endpoints over the past two decades. PMID 41358945 · Oncologist · 2025-Dec-01 This is a retrospective observational study and review analyzing multiple prior drug approvals and trials, not an original report of a single randomized controlled trial. It does not present primary time-to-event efficacy results from a specific Phase III/IIIb or Phase II/III randomized trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Tenofovir alafenamide for prevention of HBV reactivation in HBsAg-negative, anti-HBc-positive patients undergoing rituximab-based chemotherapy: A multicenter randomized controlled trial. PMID 41335575 · Hepatol Commun · 2025-Dec-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild-type and TERT promoter mutation histological grade 2/3 gliomas: An extension retrospective analysis of a randomized controlled trial. PMID 41328764 · Cancer · 2025-Dec-01 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Major Bleeding With Apixaban vs Aspirin: A Subanalysis of the ARTESiA Randomized Clinical Trial. PMID 41222953 · JAMA Cardiol · 2025-Dec-01 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Exposure-response analysis of oral and intravenous imatinib in critically ill patients with COVID-19 acute respiratory distress syndrome. PMID 41109533 · Eur J Pharm Sci · 2025-Dec-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer: Long-Term Results of the Randomized DIPLOMA Trial. PMID 41060640 · JAMA Surg · 2025-Dec-01 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
E7386 Enhances Lenvatinib's Antitumor Activity in Preclinical Models and Human Hepatocellular Carcinoma. PMID 40986544 · Clin Cancer Res · 2025-Dec-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Contrasts in colorectal cancer incidence and mortality in screening trials of sigmoidoscopy vs the Nordic-European Initiative on Colorectal Cancer colonoscopy trial. PMID 40971678 · J Natl Cancer Inst · 2025-Dec-01 This is an oncology (colorectal cancer) randomized comparative study with Kaplan-Meier analysis, but it is not eligible because it lacks a drug-containing intervention (it compares screening modalities) and does not meet the Phase III/IIIb or Phase II/III trial criteria for a drug intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -